Citations

Clear

1526 citation(s) found for "Sun, Bo".

The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in BRCA1
Apostol, Adriana Ionelia , Metcalfe, Kelly , Jorgji, Dimitri , Cybulski, Cezary , Gronwald, Jacek , Lubiński, Jan , Møller, Pål , Kim, Raymond H. , Aeilts, Amber M. , Cajal, Teresa Ramón y , Pal, Tuya , Bordeleau, Louise , Karlan, Beth Y. , Couch, Fergus J., Zakalik, Dana , Fruscio, Robert , Tung, Nadine, Sun, Ping, Monteiro, Álvaro N.A. , Narod, Steven A. , Akbari, Mohammad R. , Apostol, Adriana I , Jorgji, Dimitri , Cybulski, Cezary , Gronwald, Jacek , Lubinski, Jan , Kim, Raymond H , Aeilts, Amber M , Ramón Y Cajal, Teresa , Pal, Tuya , Karlan, Beth Y , Fruscio, Robert , Monteiro, Alvaro N , Narod, Steven A , Metcalfe, Kelly A , Bordeleau, Louise , Kotsopoulos, Joanne , Singer, Christian F. , Foulkes, William D. , Sun, Ping

Mayo Clinic

Current Oncology | December 15, 2025 | Volume: 32 | Issue: 12 | Pages: 705

10.3390/curroncol32120705 | PMID 41440233 Get It

Background: Carriers of a pathogenic variant (PV) in BRCA1 face a high risk of breast cancer. This study estimated the risk of developing breast cancer according to mutation type and location. Methods: BRCA1 carriers with no personal history of breast cancer or bilateral mastectomy were included. Detailed information on clinical and family history was collected by questionnaire. Survival analysis was used to estimate 15-year cumulative risk according to PV type and location. Results: A total of 3677 BRCA1 carriers were followed for a mean of 7.2 years (range 0.1–15.0 years); 481 incident breast cancers were documented. Overall, the 15-year cumulative incidence was 25%. Risk estimates varied by exon, ranging from 9% (exon 21) to 19% (exon 12) to 36% (exon 15); however, strata were small. Carriers of four founder mutations common in Eastern Europe (c.5263_5264insC, c.181T > G, c.66_67delAG and c.4034delA) experienced a lower-than-expected cancer risk (15.9–24.4%) compared to other PVs (28.8%) (p = 0.02). Conclusions: Although our data suggests some variability in penetrance based on specific BRCA1 PV, this was based on a large number of founder mutations. Breast cancer management strategies should continue to be based on comprehensive risk assessment.
Prospective Identification of Dysplasia in Barrett's Esophagus With Combined Optical Coherence Tomography and Light Scattering Measurements
Wax, Adam , Zhang, Haoran , Jelly, Evan T. , Price, Hillel , Sun, Tengfei , Chu, Kengyeh K., Eluri, Swathi , Goldblum, John R. , Shaheen, Nicholas J. , Cotton, Cary C.

Mayo Clinic

Journal of Biophotonics | December 15, 2025 | Volume: 19 | Issue: 3 | Pages: No page available

10.1002/jbio.202500380 | PMID 41392510 Get It

ABSTRACT Accurate identification of dysplasia in Barrett's esophagus (BE) remains a challenge. Advanced optical imaging techniques may allow for better localization of dysplasia in BE. Here, we have assessed the potential clinical utility of a previously described multimodal imaging probe combining optical coherence tomography (OCT) with angle‐resolved low coherence interferometry (a/LCI) to prospectively identify dysplasia in BE. Imaging was conducted on 37 patients undergoing endoscopic surveillance of BE, yielding co‐registered biopsies of 50 esophageal sites. The a/LCI nuclear morphology data were compared to a previous decision line to prospectively predict dysplasia, demonstrating 100% sensitivity, 93% specificity, and 94% overall accuracy. The NPV was 100%, comparable to previous a/LCI studies. The addition of OCT imaging markedly improved PPV and specificity, compared to previous studies with a/LCI alone, illustrating the clinical utility of the combined platform. These findings suggest that combining OCT and a/LCI enables better detection of dysplasia by providing better guidance.
Primary Cutaneous NUT Adnexal Carcinoma: A Case Report With Novel Clinical and Pathological Observations
Middleton, Michael L. , Sun, Christina, Busam, Klaus J. , Busam, Klaus J , Motaparthi, Kiran , Purvis, Caitlin G. , Sun, Christina, Doonan, Bently P.

Mayo Clinic

Journal of Cutaneous Pathology | December 15, 2025 | Volume: 53 | Issue: 4 | Pages: 329-333

10.1111/cup.70039 | PMID 41392342 Get It

ABSTRACT Primary cutaneous NUT adnexal carcinoma is an emerging provisional tumor entity characterized by NUTM1 rearrangement with fusion partners different from poroid neoplasms. These tumors should be distinguished from NUT carcinomas with a histopathologic appearance of poorly differentiated squamous cell carcinoma, which tend to behave more aggressively and demonstrate a widespread anatomic distribution. Since fewer than 20 cases of NUT adnexal carcinoma have been reported in the literature, we report herein another case to enhance our knowledge of the spectrum of clinical and pathologic features associated with this tumor. This case is characterized by an unusual clinical course. The lesion was present and slowly progressed over the course of 13 years prior to biopsy and excision. The tumor was composed of epithelial and myoepithelial elements with a range of features, including ductal, cribriform, and solid, with papillary, secretory, and keratocystic changes. The patient underwent wide local excision and sentinel lymph node biopsy, which revealed metastatic tumor. Molecular testing identified a BRD3‐NUTM1 fusion, confirming the diagnosis of NUT adnexal carcinoma. The patient remains disease‐free at 1‐year follow‐up without further therapy.
Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2
Kotsopoulos, Joanne , Seca, Marta , Gronwald, Jacek, Møller, Pål , Kim, Raymond H. , Singer, Christian F., Karlan, Beth Y. , Aeilts, Amber M. , Cajal, Teresa Ramón y , Eisen, Andrea , Bordeleau, Louise , Tung, Nadine, Neuhausen, Susan L., Zakalik, Dana , Olopade, Olufunmilayo, Metcalfe, Kelly , Sun, Ping, Narod, Steven A., Olopade, Olufunmilayo I. , Singer, Christian F. , Huzarski, Tomasz , Kim, Raymond H , Singer, Christian F , Karlan, Beth Y , Aeilts, Amber M , Ramón Y Cajal, Teresa , Eisen, Andrea , Bordeleau, Louise , Foulkes, William D , Tung, Nadine , Couch, Fergus J. , Neuhausen, Susan L. , Cybulski, Cezary , Olopade, Olufunmilayo I , Fruscio, Robert , Lubinski, Jan , Narod, Steven A , Metcalfe, Kelly A , Kotsopoulos, Joanne , Huzarski, Tomasz , Pal, Tuya , Foulkes, William D. , Tung, Nadine , Couch, Fergus J. , Cybulski, Cezary , Fruscio, Robert , Lubiński, Jan , Narod, Steven A.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 13, 2025 | Volume: 118 | Issue: 5 | Pages: 856-864

10.1093/jnci/djaf363 | PMID 41403285 Get It

Abstract Background Women with a pathogenic variant in BRCA1 or BRCA2 are at high risk of developing ovarian cancer, and it is often recommended that they undergo bilateral salpingo-oophorectomy at an early age, resulting in surgical menopause. Menopausal hormone replacement therapy (HRT) is an effective way to mitigate the adverse outcomes of early menopause; however, the safety of menopausal HRT on breast cancer risk in this population has not been established. Methods We conducted a prospective matched analysis of HRT use following menopause and breast cancer risk in BRCA carriers. Women who initiated HRT were matched one-to-one with women who had not initiated menopausal HRT by gene, year of birth, and age at menopause, resulting in 676 matched pairs. Menopausal HRT use collected by questionnaire included formulation and mode of administration. Results After a mean of 5.6 years, there were 87 (12.9%) incident breast cancer cases in the 676 exposed women and 128 (18.9%) cases in the 676 unexposed women (P = .002). Compared with unexposed matched control individuals, women who used estrogen alone experienced a statistically significantly decreased risk of breast cancer (hazard ratio = 0.37, 95% CI = 0.24 to 0.57). No protective or adverse effect was associated with the use of estrogen plus progestogen (hazard ratio = 0.94, 95% CI = 0.54 to 1.63). Conclusions Our findings suggest no substantial increase in the risk of breast cancer in BRCA carriers with the use of HRT and that estrogen alone might be protective.
Type B Aortic Dissection in Patients Aged 30 Years or Younger: A Retrospective Multicentre Study
Yıldız, Murat , Luehr, Maximilian , Ma, Wei‐Guo , Martens, Andreas , Ruhparwar, Arjang , Pellenc, Quentin , Girault, Antoine , Mosbahi, Selim, Desai, Nimesh D. , Polycarpou, Andreas , Pochettino, Alberto , Cameron, Duke E., Heck, Roland , Bischoff, Moritz S., Osada, Hiroaki, Minatoya, Kenji , Peterß, Sven , Jassar, Arminder S. , Berger, Tim, Sun, Li-Zhong , Schoenhoff, Florian , Okita, Yutaka , Murana, Giacomo , Osada, Hiroaki , Minatoya, Kenji , Peterss, Sven , Dumfarth, Julia , Jassar, Arminder , Zierer, Andreas , Berger, Tim , Kolowca, Maciej , Sun, Li-Zhong , Schoenhoff, Florian , Kempfert, Jörg

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | December 12, 2025 | Volume: 68 | Issue: 1 | Pages: No page available

10.1093/ejcts/ezaf450 | PMID 41392201 Get It

Abstract Objectives Type B aortic dissection (TBAD) is rare in patients aged ≤30 years, and data on this population remain limited. This study aimed to characterize the underlying aetiology, and outcomes of invasively treated young patients with TBAD, with a focus on the impact of heritable thoracic aortic disease (HTAD). Methods A retrospective multicentre analysis was conducted across 19 international aortic centres, including 139 patients aged ≤30 years with TBAD. Patients with chronic TBAD (n = 42) were excluded for the final analysis. The cohort was classified as uncomplicated (n = 86) or complicated (n = 53) TBAD. Clinical, radiologic, intraoperative, and postoperative data were collected using standardized forms. Outcomes were compared between subgroups defined by TBAD complexity, HTAD status, and surgical strategy. Kaplan-Meier and Andersen-Gill analyses were used for survival and recurrent aortic intervention, respectively. Results Mean follow-up time was 6.5 years. HTAD was identified in 57% of patients. Most presented with uncomplicated TBAD (62%), while high-risk uncomplicated cases were uncommon. Endovascular repair was predominant in complicated TBAD, while open repair was more frequent in uncomplicated cases. Early mortality was low (n = 3), and mid-term survival was excellent across all subgroups. HTAD was a significant predictor of recurrent aortic interventions (HR = 3.3, P = .004). No significant differences were observed in survival or reintervention rates between uncomplicated and complicated TBAD or between operative strategies. Conclusions In young patients, TBAD predominantly occurs in the context of HTAD. Both open and endovascular repair are associated with excellent early outcomes and mid-term survival. However, HTAD remains a significant predictor of recurrent aortic interventions.
Endometriosis in Carriers of a Pathogenic Variant in BRCA1 or BRCA2: A Descriptive Analysis of a Large Multicentral BRCA Carrier Cohort
Mokhber, Aghaghia , Stewart, Bethany , Gronwald, Jacek , Cybulski, Cezary , Kim, Raymond H. , Karlan, Beth Y. , Bordeleau, Louise , Cajal, Teresa Ramón y , Pal, Tuya , Eisen, Andrea , Couch, Fergus J., Zakalik, Dana , Tung, Nadine, Fruscio, Robert , Sun, Ping, Lubiński, Jan , Narod, Steven A. , Stewart, Brynne , Gronwald, Jacek , Cybulski, Cezary , Kim, Raymond H , Karlan, Beth Y , Ramón Y Cajal, Teresa , Pal, Tuya , Eisen, Andrea , Fruscio, Robert , Lubinski, Jan , Narod, Steven A , Bordeleau, Louise , Terry, Kathryn L. , Couch, Fergus J. , Tung, Nadine , Foulkes, William D. , Aeilts, Amber M. , Sun, Ping , Kotsopoulos, Joanne

Mayo Clinic

Current Oncology | December 5, 2025 | Volume: 32 | Issue: 12 | Pages: 675

10.3390/curroncol32120675 | PMID 41440203 Get It

Background: Endometriosis affects an estimated 10% of reproductive-aged women and is associated with increased ovarian cancer risk. While BRCA1/2 mutations are established risk factors for ovarian cancer, their association with endometriosis remains unclear. This study aimed to characterize the prevalence and clinical features of endometriosis within a large cohort of BRCA mutation carriers. Methods: A descriptive analysis was conducted using data from a multi-center longitudinal cohort of women with pathogenic BRCA variants. Reproductive history and related factors were collected through self-reported questionnaires and compared. Results: Among 16,950 BRCA carriers, the prevalence of endometriosis was 2.4%. Compared to BRCA carriers without endometriosis, those with endometriosis were more likely to carry a BRCA2 mutation, have post-secondary education, and experience earlier menarche. BRCA carriers with endometriosis had a lower ovarian cancer prevalence than those without (10% vs. 15%, p < 0.001). Conclusions: This is the first study of this scale to report the prevalence of endometriosis among BRCA mutation carriers, which was lower than previously reported in the general population. The association between endometriosis and ovarian cancer does not appear to be generalizable to this population. Further prospective studies are warranted to clarify this association among BRCA mutation carriers.
Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia
Advani, Anjali, Chen, Li, Sun, Zhuoxin, Mattison, Ryan, Paietta, Elisabeth, Zhang, Yanming, Racevskis, Janis, Lazarus, Hillard, Rowe, Jacob, Arber, Dan, Wieduwilt, Matthew, Liedtke, Michaela, Bergeron, Julie, Wood, Brent, Pratz, Keith, Dinner, Shira, Frey, Noelle, Gore, Steven, Bhatnagar, Bhavana, Atallah, Ehab, Uy, Geoffrey, Jeyakumar, Deepa, Lin, Tara, Willman, Cheryl, Podoltsev, Nikolai, Deangelo, Daniel, Patel, Shejal, Elliott, Michelle, Tzachanis, Dimitrios, Vachhani, Pankit, Bhave, Rupali, Sharon, Elad, Little, Richard, Erba, Harry, Stone, Richard, Luger, Selina, Mullighan, Charles, Tallman, Martin, Litzow, Mark, Advani, Anjali, Chen, Li, Sun, Zhuoxin, Mattison, Ryan, Paietta, Elisabeth, Zhang, Yanming, Racevskis, Janis, Lazarus, Hillard, Rowe, Jacob, Arber, Dan, Wieduwilt, Matthew, Liedtke, Michaela, Wood, Brent, Pratz, Keith, Dinner, Shira, Frey, Noelle, Gore, Steven, Bhatnagar, Bhavana, Atallah, Ehab, Uy, Geoffrey, Jeyakumar, Deepa, Lin, Tara, Willman, Cheryl, Podoltsev, Nikolai, Deangelo, Daniel, Patel, Shejal, Elliott, Michelle, Tzachanis, Dimitrios, Vachhani, Pankit, Bhave, Rupali, Sharon, Elad, Little, Richard, Erba, Harry, Stone, Richard, Luger, Selina, Mullighan, Charles, Tallman, Martin, Litzow, Mark

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5120-5120

10.1182/blood-2025-5120 Get It

Abstract E1910 evaluated the addition of blinatumomab to chemotherapy in adults with B-acute lymphoblastic leukemia (ALL). The addition of blinatumomab in patients (pts) with measurable residual disease (MRD) negative (neg) B-ALL significantly improved both relapse-free and overall survival (NEJM 2024; 391: 320-33)1. Given the increasing use of blinatumomab and the E1910 backbone chemotherapy regimen, we evaluated &gt; Grade 3 toxicities on this trial in further detail. We assessed toxicity among the MRD-neg pts by age, gender, body mass index (BMI), combined cytogenetic-molecular risk, and number of cycles of blinatumomab received. We also evaluated toxicities during induction since this trial used a modified chemotherapy backbone. Methods: The eligibility, combined cytogenetic-molecular risk, and treatment have been previously described.1 All toxicities were &gt; Grade 3 by CTCAE version 4 with at least a possible relationship to treatment. Descriptive statistics were used to summarize the occurrence and rates of toxicities and Fisher's exact test was used to compare differences in proportions between groups. Analysis of induction included all pts who started treatment. Analysis of Step 3 toxicities included MRD-neg pts who started treatment on the blinatumomab (n=111) or chemotherapy only arm (n=112). Results: Pt characteristics: For induction (n=488), median age was 51 years (yrs) (range 30-70); 48.6% female. Combined cytogenetic-molecular risk: favorable (13.5%); intermediate (12.9%); no risk assigned (16.2%); unfavorable (57.4%). For induction, we compared toxicities for E1910 (n=488) to pts treated on a prior young adult study (n=289) (C10403) (Blood Adv 2021; 5(2): 504-12). The incidence of hyperglycemia (8% vs. 31.1%, p&lt; 0.001), aspartate aminotransferase (AST) increase (6.1% vs. 12.8%, p=0.002), alanine aminotransferase increase (ALT) (11.7% vs. 28.7%, p&lt; 0.001), and hyperbilirubinemia (11% vs. 19%, p=0.002) were significantly lower in E1910 pts. The incidence of pancreatitis (1.8%), thromboembolic events (4.5%), and febrile neutropenia (25.4%) in E1910 was similar to C10403. Toxicities in the MRD-neg pts in the blinatumomab arm (n=111): Despite a high incidence of neutropenia (74.8%) and thrombocytopenia (55.9%) in Step 3, there was a relatively low incidence of sepsis (7.2%), bacteremia (1.8%), cytokine release syndrome (CRS) (3.6%) and neurologic adverse events (0-6.3%). There was a higher incidence of neurological or psychiatric events in the blinatumomab arm (23%) versus chemotherapy arm (5%) (p &lt; 0.001) when all events were combined. There was a numerically higher incidence of ataxia (4.4% vs. %, p=0.16) and dysphasia (11.1% vs. 3%, p=0.12) in pts &gt; 55 yrs and a higher incidence of neutropenia (80.3% vs. 66.7%, p=0.12) and thrombocytopenia (62.1% vs. 46.7%, p=0.12) in the younger pts (age &lt; 55 yrs). In pts with a BMI &lt; 30 kg/m2 (vs. &gt; 30 kg/m2), there was a significantly higher incidence of leukopenia (51.7% vs. 26.4%, p=0.007) and thrombocytopenia (65.5% vs. 45.3%, p=0.037). However, this did not translate into an increased incidence of bleeding or infectious complications. By gender, females had a higher numerical incidence of AST increase (8.8% vs. 0%, p=0.057) and CRS (7% vs. 0% p=0.12); whereas males had a higher incidence of catheter- related infections (7.4% vs. 0%, p=0.05) and hyperglycemia (11.1% vs. 3.5%, p=0.16). A little more than half (56.8%) of pts received 4 cycles of blinatumomab with the remainder of pts receiving 1 (10.8%), 2 (28.8%), or 3 cycles (3.6%). Pts receiving 3-4 cycles of blinatumomab vs. 1-2 cycles of blinatumomab had a statistically higher incidence of anemia (38.8% vs. 6.8%, p&lt; 0.001), neutropenia (98.5% vs. 38.6%, p&lt; 0.001), and thrombocytopenia (83.6% vs. 13.6%, p&lt; 0.001), likely related to being on treatment for a longer period of time. Conclusions: Blinatumomab was well tolerated with no significant toxicity differences noted by age, gender, or number of cycles of blinatumomab received. Pts with a lower BMI did have an increased incidence of leukopenia and thrombocytopenia, possibly related to flat dosing of the drug. However, this did not translate into increased complications. Toxicites during induction were notably few, which suggests that this backbone with age adjustments may serve as a good backbone for future trials. Blinatumomab is being evaluated with low dose chemotherapy and other targeted agents in ongoing trials.
Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial
Zhong, Xiaoming , Sun, Zhuoxin , Wei, Huimei, Chang, Ti‐Cheng , Lei, Shaohua, Rampersaud, Evadnie , Fan, Yiping, Wu, Gang , Mattison, Ryan J. , Zhang, Yanming , Racevskis, Janis, Rowe, Jacob M. , Wieduwilt, Matthew J. , Liedtke, Michaela , Bergeron, Julie , Pratz, Keith W. , Dinner, Shira, Frey, Noelle, Gore, Steven D. , Bhatnagar, Bhavana , Jeyakumar, Deepa , Patel, Shejal, Elliott, Michelle A. , Vachhani, Pankit , Roy, Rupali , Little, Richard F. , Stone, Richard M. , Tallman, Martin S. , Paietta, Elisabeth, Luger, Selina M. , Litzow, Mark R. , Roberts, Kathryn G. , Montefiori, Lindsey E. , Pölönen, Petri , Zhang, Wenchao, Lazarus, Hillard M. , Arber, Daniel A. , Wood, Brent L. , Frey, Noelle, Atallah, Ehab , Uy, Geoffrey L. , Lin, Tara L. , Willman, Cheryl L. , Podoltsev, Nikolai , DeAngelo, Daniel J. , Advani, Anjali S. , Tzachanis, Dimitrios , Sharon, Elad , Erba, Harry Paul , Yang, Jun J.J. , Mullighan, Charles G.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 31-31

10.1182/blood-2025-31 Get It

Abstract Introduction:A comprehensive integration of significantly mutated genes and pathways with molecular subgroups is lacking in adult B-ALL. Furthermore, the genomic drivers underlying each subgroup remain to be identified.We aimed to perform genomic analysis on a large cohort of patients with adult B-ALL, and to correlate genomic markers with achievement of MRD negativity enabling blinatumomab randomization, and with subsequent response to blinatumomab. Methods:For genomic analysis, we studied 569 adults with newly diagnosed B-ALL registered for initial screening on the ECOG-ACRIN-led E1910 trial (NCT02003222), which evaluated the addition of blinatumomab to standard consolidation chemotherapy. The median age was 52 yrs (range 30 to 71 yrs), with 52% males. Analysis was performed on tumor and matched-normal samples using whole transcriptome sequencing (RNA-seq; tumor only; n=569), whole exome sequencing (n=490), whole genome sequencing (n=131), and single nucleotide polymorphism array (n=445). B-ALL cases were classified into 22 molecular groups. Outcome analysis was limited to patients enrolled and treated on E1910 (n=319). Results: Driver genes (n=268) were identified by the mutation-significance detection tool dNdScv or by the presence of pathogenic variants in known cancer genes, with NUP188 identified as a novel driver gene. Recurrently mutated pathways included: B-cell development (46%), cell cycle (44%), epigenetic regulation (30%), other transcriptional regulation (27%), Ras signaling (25%), RNA machinery (17%) and JAK-STAT signaling (8%). A high frequency of high-risk subtypes was observed including BCR::ABL1 (20%), BCR::ABL1-like (18%), low hypodiploid (14%) and KMT2A (12%). Using tSNE analysis, we identified a new cluster of cases (n=20, 3.5%) lacking a known subgroup driver, with overexpression of CEBPA (n=13) or CEBPB (n=7), distinct from CEBPE/ZEB2, termed “CEBP-altered” ALL (CEBPalt). Five of 13 cases with high CEBPA expression harbored an IGH::CEBPA rearrangement and one harbored a RXRA::CEBPA enhancer hijacking alteration. Of the 7 cases with high CEBPB expression, 5 harbored IGH::CEBPB, and two of these had concomitant clonal BCR::ABL1 fusions. To identify additional mechanisms of CEBP deregulation, in situ Hi-C coupled to H3K27 acetylation immunoprecipitation (HiChIP) was performed on 5 cases. Four cases showed evidence of de novo CEBPA enhancer activity. In two cases, we identified novel insertions (12 and 34nt) ~2kb downstream of CEBPA. A novel translocation and enhancer hijacking event between LINC00426 and the 5' UTR of CEBPB was identified in the remaining case. Overall, we confirmed genomic alterations of CEBPA or CEBPB in 16 of 20 cases with available material. Thus, we have identified a new molecular subgroup of adult B-ALL characterized by genomic alterations that drive enhancer hijacking and oncogenic deregulation of CEBPA/CEBPB. Several subgroups were enriched in patients that failed induction chemotherapy (n=62) or were MRD-positive (n=63) compared to those that achieved MRD-negative status (n=194): BCR::ABL1-like (30 vs 14%, p&lt;0.001), KMT2A (18 vs 9%, p=0.03) and BCL2/MYC (5 vs 1%, p=0.06). Conversely, the following subgroups were enriched in patients that achieved MRD-negativity: PAX5alt (6 vs 18%, p=0.002), TCF3::PBX1 (0 vs 5%, p=0.01) and ZNF384 (2 vs 6%, p=0.08) Within each molecular subgroup we compared the survival of patients who achieved MRD-negative status after induction and were randomized to receive blinatumomab plus chemotherapy (n=93) or chemotherapy only (n=91). Although numbers were low, blinatumomab improved relapse-free survival for patients with hyperdiploid, PAX5alt, BCR::ABL1-like and KMT2A ALL compared to chemotherapy alone. Clonal hematopoiesis of indeterminate potential (CHIP)-related gene mutations were identified in 121 of 417 cases analyzed (29% total: somatic 74%, remission 31%, both 5%). TP53 mutations were most frequent (n=65 patients), with the majority identified in patients with low hypodiploid (n=52). Interestingly, patients with CRLF2 rearrangements collectively harbored the highest number of other CHIP gene mutations (n=13), including DNMT3A (n=4), TET2 (n=3) and ASXL1 (n=3). Conclusions:We provide a comprehensive landscape of genomic alterations in adult B-ALL and identify a new group characterized by deregulation of CEBPA/CEBPB (CEBPalt). We also provide insights into the efficacy of blinatumomab in different molecular subgroups of adult B-ALL.
Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.
Baslan, Timour , Belleau, Pascal, Zhang, Yanming , Sun, Zhuoxin , Kleppe, Maria, Paietta, Elisabeth , Cripe, Larry D., Fernández, Hugo F. , Tallman, Martin S. , Rowe, Jacob M. , Litzow, Mark R. , Dimitrova, Nevenka , Luger, Selina M. , Deschênes, Astrid , Garrett-Bakelman, Francine E. , Lazarus, Hillard M. , Melnick, Ari , Levine, Ross L. , Krasnitz, Alexander , Lowe, Scott W.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5263-5263

10.1182/blood-2025-5263 Get It

Abstract Copy Number Alterations (CNAs), including chromosomal gains and losses, shape the genetics and clinical management of acute myeloid leukemia (AML), particularly in complex karyotypes (e.g. CK-AML). Traditionally, AML associated CNAs have been studied using cytogenetic approaches, i.e., karyotyping, that are limited in resolution and sensitivity. Here, low-coverage, sparse whole genome sequencing followed by machine learning applied to over 600 AML patient samples (ECOG-ARCIN trials: E1900, E3999) reveals novel genetic, biologic, and clinical correlates in AML disease. We find that multi-variate Cox-regression analysis applied to the data identifies select patients exhibiting focal and cryptic hemizygous deletions at 17q, 21q, and 3p, in otherwise diploid genomes, associate with inferior survival compared to other patients (median overall survival; OS = 65.5 compared to 421 days, Chi-square test pval=6x10-11), independent of factors such as age, treatment, and karyotype complexity status. In addition, we confirm that amplifications at 11q23, encoding the KM2TA gene, are associated with inferior outcome, and further identify unique breakpoint event features as well as transcriptional signatures suggestive of distinctive KM2TA-translocation independent biology. Applying machine learning approaches to the data, more specifically Non-negative Matrix Factorization (NMF), we develop a prognostic model that captures clinically adverse, cryptic variation such as focal 5q deletions, missed by conventional chromosome analysis and thereby, adds novel, complementary information to traditional, cytogenetic based risk-stratification (e.g. ELN). The model also associates gain of chromosome 8 in Intermediate risk patients with worse outcome compared to other Intermediate risk patients (median OS = 186 compared to 446 days, Chi-square test pval=0.005) and identifies a subgroup of patients within the adverse risk category that lack deletions on chromosomes 5, 7, and 17, and that fare better than the rest of the adverse risk patients (median OS = 188 compared to 97.5 days, Chi-square test pval=0.02), likely reflecting previously identified “atypical” CK-AML patients. Last, we develop a prognostic classifier based on a combination of Neural-Network and Random-Forest based learning, that predicts disease outcome with high accuracy and is based on a three genomic feature list on chromosome bands 5q31.2, 7q31.33, and 8q24, suggesting potential for clinical implementation. Altogether, our results show that low coverage, sparse whole genome sequencing combined with advanced learning methods can be applied clinically to support the diagnosis and clinical management of AML disease as well as serve as a powerful tool to further a basic understanding of the genetics and biology of CNAs in myeloid neoplasms and other cancers.
Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab
Bhatnagar, Bhavana , Sun, Zhuoxin , Mattison, Ryan J. , Paietta, Elisabeth, Zhang, Yanming , Racevskis, Janis, Rowe, Jacob M. , Wieduwilt, Matthew J. , Liedtke, Michaela , Bergeron, Julie , Pratz, Keith W. , Dinner, Shira, Gore, Steven D. , Jeyakumar, Deepa , Patel, Shejal, Elliott, Michelle A. , Vachhani, Pankit , Roy, Rupali , Little, Richard F. , Stone, Richard M. , Luger, Selina M. , Tallman, Martin S. , Litzow, Mark R. , Lazarus, Hillard M. , Arber, Daniel A. , Wood, Brent L. , Frey, Noelle V. , Atallah, Ehab , Uy, Geoffrey L. , Lin, Tara L. , Willman, Cheryl L. , Podoltsev, Nikolai , DeAngelo, Daniel J. , Advani, Anjali S. , Tzachanis, Dimitrios , Sharon, Elad , Erba, Harry Paul , Mullighan, Charles G.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1549-1549

10.1182/blood-2025-1549 Get It

Abstract Background: The addition of the CD19/CD3 bispecific T-cell engager, blinatumomab, to standard consolidation chemotherapy in adults with ALL who achieved a measurable residual disease negative (MRDneg) remission (CR), demonstrated an improvement in 3-year overall survival (OS, 85% vs 68%, HR 0.41, P=0.002) and 3-year relapse-free survival (RFS, 80% vs 64%, HR 0.53) compared to conventional chemotherapy in the ECOG-ACRIN E1910 study (Litzow et al, NEJM 2024). Given the complex therapy in this study, treatment delays and modifications are expected. We herein explored the impact of such delays on patient outcomes. Methods: In the phase 3 ECOG-ACRIN E1910 trial (NCT02003222), adults aged 30-70 years with newly diagnosedALL who had achieved MRDneg CR following induction and intensification were randomized to consolidation chemotherapy with blinatumomab (blina arm) or chemotherapy alone (chemo arm). We examined the association between the timing of the initiation of maintenance therapy and OS and RFS. The expected duration of consolidation was 252 days vs 126 days for patients on the blina and chemo arms, respectively. For this analysis, participants were classified into two groups (no/short delay or long delay) depending on whether they started on time/before or after the median time between the beginning of consolidation and start of maintenance therapy for their treatment group (medians: 335 days, range, 181-457 days vs 176 days, range, 139-265 days for blina and chemo arms, respectively). Multivariate analyses of OS and RFS were performed to examine the effect of no/short delay vs. long delay in starting maintenance. Patients were stratified according to their assigned consolidation treatment arm, and the models were further adjusted for age, sex, white blood cell count, platelets, hemoglobin, peripheral blood blasts, bone marrow blasts, performance status and genetic-genomic risk at diagnosis. Results: Of the 488 patients enrolled, 224 MRDneg patients were randomized to consolidation chemotherapy with or without blinatumomab and 135 of the 224 went on to maintenance therapy on study (N= 66 on blina arm and 69 on chemo arm, respectively). The median follow-up from the time of maintenance registration was 43.4 months. There were no significant differences in baseline characteristics between patients in either arm who experienced no/short delay or long delay. In the blina group, 60 of 66 patients (90.9%) received all 8 cycles of consolidation therapy of which 31 (45.6%) had long delays. Sixty-eight of 69 patients on the chemo arm (98.5%) received all cycles of consolidation therapy, of which 34 (50%) had a long delay. Strikingly, patients who had a long delay before initiation of maintenance had a significant improvement in OS in multivariate analysis compared to patients who had no/short delay (HR 0.31, 95% CI: 0.11-0.91; P =0.03). However, within each treatment group, OS benefit did not reach statistical significance (blina arm: HR 0.04, 95% CI: 0.001-1.64; P =0.09; chemo arm: HR 0.32, 95% CI: 0.08-1.38; P =0.13). Similar results were observed for RFS in multivariate analysis (HR 0.40, 95% CI: 0.16-1.01; P =0.05), though this impact on improved RFS was noted in the chemo arm but not in blinatumomab treated patients (blina arm: HR 0.56, 95% CI: 0.10-3.24; P =0.52; chemo arm: HR 0.19, 95% CI: 0.04-0.83; P=0.03). Additionally, patients who had no/short delay before starting maintenance experienced a longer median duration of maintenance treatment (blina arm, 548 days; chemo arm, 708 days) compared to patients who had a long delay (blina arm 488 days; chemo arm 598 days) before initiation of maintenance (P=0.0008). Conclusion: In the phase 3 randomized ECOG-ACRIN E1910 clinical trial, long delays between initiation of consolidation therapy and start of maintenance therapy were associated with improved OS compared to no/short delays. However, within each treatment group (blina or chemo), no significant difference of OS was observed. We postulate that these longer delays allowed more patients to receive all of the recommended protocol-assigned therapy thereby resulting in improved survival. Furthermore, patients who had no/short delays had a significantly longer duration of maintenance therapy. These data indicate that treatment delays during consolidation do not worsen survival. Further studies are being done to better understand why patients with long delays had better overall survival.